As Lipitor Lawsuits Mount in U.S. Courts, Bernstein Liebhard LLP Notes that the Statin Now Ranks As Most Prescribed Drug in New Jersey
New York, New York (PRWEB) November 15, 2014 -- As Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that the statin medication now ranks as the most prescribed medication in the state of New Jersey. According to a report from NJ.com, the determination was made by the state’s Prescription Drug Registry, which maintains a list of New Jersey’s 150 most-commonly prescribed medications. The data is compiled from the most recent claims submitted by licensed New Jersey pharmacies to the state Division of Medical Assistance and Health Services.*
“Well over 1,000 Lipitor lawsuits are now pending in U.S. courts, all of which allege the medication caused patients to develop new-onset Type 2 diabetes. The large number of filings partly reflects the widespread use of Lipitor, so its ranking as the most-prescribed drug in New Jersey is not at all surprising,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who may have been harmed by Lipitor.
Lipitor Diabetes Litigation
Lipitor, which was brought to market in 1996, is a statin drug used to treat high cholesterol. In January 2012, a study published in JAMA: Internal Medicine reported that post-menopausal women who take Lipitor may be at an increased risk for developing diabetes.** On February 29, 2012, the U.S. Food & Drug Administration (FDA) ordered the manufacturers of Lipitor and other statins to add new warnings to its label regarding this potential risk.
Court documents indicate that more than 1,300 product liability lawsuits involving Lipitor and diabetes are now pending in the U.S. District Court, Southern District of South Carolina, where all federally-filed claims have been consolidated for coordinated pre-trial proceedings. Plaintiffs in these cases allege that Pfizer Inc. was aware that the statin could increase a patient’s risk for developing Type 2 diabetes, but concealed this information from patients and doctors. They further allege that information added to the Lipitor label in 2012 to address its association with diabetes was inadequate, and still does not adequately warn of this risk. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
Patients who took Lipitor and developed new-onset Type 2 diabetes may be entitled to compensation for medical bills, lost wages, and pain and suffering. Learn more about filing a Lipitor lawsuit at Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free, no-obligation case review.
*nj.com/healthfit/index.ssf/2014/11/what_are_the_25_most_prescribed_drugs_in_nj.html, NJ.com, November 4, 2014
**archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.lipitorlawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Lipitor Lawsuit Diabetes Information Center, http://www.lipitorlawsuitcenter.com/, +1 800-511-5092, [email protected]
Share this article